Teplizumab is an intravenously administered anti-CD3 monoclonal antibody indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with stage 2 T1D.

If you have a Hayes login, click here to view the full report on the Knowledge Center.